Back to articles

Risks associated with use of ESAs in patients with cancer confirmed



A recent FDA advisory committee meeting on the safety of erythropoeisis-stimulating agents (ESAs) for patients with cancer recommends that the current FDA-approved indication for ESAs be modified to include a statement that these agents should not be used in patients receiving potentially curative treatments or for patients with metastatic breast and/or head and neck cancers.